When the host is not healthy: Rethinking tuberculosis drug targets in comorbid conditions

Tuberculosis · Published 2026-05-05 · DOI 10.1016/j.tube.2026.102781

Authors being retrieved — see the publisher record. https://doi.org/10.1016/j.tube.2026.102781

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year: 2026

Related articles

Novel plasma biomarkers for the diagnosis of pulmonary tuberculosis · Tuberculosis · 2026 · Same journal
Dysregulated IFN-γ, IL-6 and TNF-α after COVID-19 is suggestive of lowered innate immune responses to SARS-CoV-2 and MTB · Tuberculosis · 2025 · Same journal
Identification of an autophagy-related novel signature for spinal tuberculosis: a multi-cohort machine learning study and Mendelian randomization analysis · Tuberculosis · 2026 · Same journal
Towards model-informed precision dosing of clofazimine, moxifloxacin, and terizidone/cycloserine in the treatment of drug-resistant tuberculosis: An external model evaluation study · Tuberculosis · 2026 · Same journal
Understanding the role of PezAT and MbcTA toxin-antitoxin systems in the pathophysiology of Mycobacterium tuberculosis · Tuberculosis · 2025 · Same journal
In vitro and in vivo efficacy of PI3Kγ inhibitor AS605240 in controlling mycobacterial infections · Tuberculosis · 2025 · Same journal
WSI AFB and AI deliver highest sensitivity for TB detection · Tuberculosis · 2026 · Same journal
Drug resistance in tuberculous meningitis: A laboratory-based observational study from Northern India's tertiary care referral centre · Tuberculosis · 2026 · Same journal
A fusion protein LT25 containing Rv2660c failed to provide protection against Mycobacterium bovis infection due to limited humoral immune responses · Tuberculosis · 2026 · Same journal
The role of programmed cell death pathways in the host response to Mycobacterium tuberculosis: Insights from gene expression analysis in active pulmonary tuberculosis patients · Tuberculosis · 2026 · Same journal